Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All tumor tissues were immunoreactive for either one or both neuroendocrine biomarkers (chromogranin A and synaptophysin) and Ki67 index was >20% in all cases. p53 immunoreactivity was only shown in 39% of the cases and was not found to be a prognostic marker for the whole cohort.
|
29112960 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the tumor was strongly positive for keratin 7 (CK7) and pankeratin AE1/AE3, and alpha 1 antichymotrypsin; negative for synaptophysin and chromogranin A, CDx2, CK20, S100, carcinoembryonic antigen (CEA), MUC 2, MUC5AC, and somatostatin; and in part positive for CA19-9.
|
29145864 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The histopathological diagnosis includes the immunohistochemical profile of the tumor in regard to synaptophysin and chromogranin A, as well as the Ki-67 index.
|
29374682 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A detailed immunohistochemical analysis showed that the tumor was strongly positive for synaptophysin, CD56 and chromogranin A, with a Ki-67 labeling index greater than 80%.
|
30024526 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We report the case of an ovarian large cell carcinoma expressing all neuroendocrine markers (CD56, chromogranin A, synaptophysin) that presented as a primary tumor and coexisted with a typical endometrial serous carcinoma also expressing one neuroendocrine marker (CD56).
|
30171991 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry of the tumour cells showed strong positivity for the neuroendocrine markers synaptophysin and a very high Ki67 proliferation index.
|
30642849 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aimed to elucidate whether the three NE markers such as chromogranin A, synaptophysin, and NCAM decide prognoses for patients with well-differentiated tumors.
|
30863885 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results show that parathyroid hormone and chromogranin A are useful markers for parathyroid neoplasms, while synaptophysin and INSM1 are not very sensitive broad-spectrum markers for these neoplasms.
|
31119524 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Two of 3 tumors showed pilocytic features with focal expression of synaptophysin staining and variable high-grade histologic features; the third tumor aligned best with glioblastoma and showed no evidence of neuronal differentiation.
|
31626289 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |